Substantial doubt about the company's ability to continue as a going concern.
“These conditions raise substantial doubt regarding the Company's ability to continue as a going concern for a period of one year from the date these unaudited condensed financial statements are issued. Management's plan to mitigate the conditions that raise substantial doubt includes generating additional revenues, deferring certain projects and capital expenditures and eliminating certain future operating expenses for the Company to continue as a going concern. However, there can be no assurance that the Company will be successful in completing any of these options. As a result, management's plans cannot be considered probable and thus do not alleviate substantial doubt about the Company's ability to continue as a going concern.”View the 10-Q filed Aug 14, 2026
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →
iSpecimen Inc. completed its acquisition of Foldlab AI Ltd.’s artificial intelligence products on November 2, 2026 for $4,500,000. The seller received $750,000 cash and 2,907,977 shares, with two milestone payments of $625,000 each contingent on delivery and acceptance.
iSpecimen Inc.’s stockholders approved a reverse stock split at a ratio ranging from one-for-ten (1:10) to one-for-one hundred (1:100), with the exact ratio determined by the Board of Directors. Votes were 1,152,016 FOR, 142,944 AGAINST, 868 ABSTAIN and 0 broker non-vote.
At iSpecimen Inc.’s December 30, 2026 annual meeting, stockholders will vote on Delaware-to-Nevada conversion, Avtar Dhaliwal’s three-year term expiring at the 2029 Annual Meeting, and ratification of Bush & Associates CPA LLC for the year ending December 31, 2026.
iSpecimen Inc. amended its proxy statement for the October 30, 2026 Adjourned Meeting to change Proposal No. 2's vote standard to a FOR-over-AGAINST majority under DGCL Section 242(d)(2) and allow broker discretionary voting on the Reverse Stock Split Proposal at a ratio of 1-for-10 to 1-for-100.
iSpecimen Inc. stockholders approved Pre-Funded Warrant issuance, future convertible financing transactions and Foldlab AI Ltd. asset acquisition on October 9, 2026; voting on the proposed reverse stock split was adjourned to October 30, 2026 at 10:00 a.m. Eastern Time.
